Sumitomo Pharma Co Ltd 2020 Integrated Report
The report covers Sumitomo Dainippon Pharma's performance and strategy for fiscal 2019 (ended March 31, 2020). Highlights include the company's major strategic alliance with Roivant Sciences, acquiring several late-stage pipeline assets such as relugolix and vibegron alongside data and digital technology platforms. Consolidated revenue reached 482.8 billion yen, driven by strong growth in key pharmaceutical products in Japan, North America, and China. In sustainability, the company established updated 2030 environmental targets, including a 35% reduction in Scope 1 and 2 GHG emissions compared to fiscal 2017 levels.
Company: Sumitomo Pharma Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2020
Type: Integrated Report
Pages: 158
Back to company
Sumitomo Pharma Co Ltd
Integrated Report
The report covers Sumitomo Dainippon Pharma's performance and strategy for fiscal 2019 (ended March 31, 2020). Highlights include the company's major strategic alliance with Roivant Sciences, acquiring several late-stage pipeline assets such as relugolix and vibegron alongside data and digital technology platforms. Consolidated revenue reached 482.8 billion yen, driven by strong growth in key pharmaceutical products in Japan, North America, and China. In sustainability, the company established updated 2030 environmental targets, including a 35% reduction in Scope 1 and 2 GHG emissions compared to fiscal 2017 levels.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Apr 1, 2019 - Mar 31, 2020
Fiscal Year
2019
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Employees